Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
San Francisco, CA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Washington,
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Boston, MA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Boston, MA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Newark, NJ
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
New York, NY
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Rochester, NY
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated:  8/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Status: Enrolling
Updated: 8/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily x 5 Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies
Status: Enrolling
Updated:  8/26/2015
Cancer Therapy and Research Center, University of Texas Health Center at San Antonio
mi
from
San Antonio, TX
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily x 5 Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies
Status: Enrolling
Updated: 8/26/2015
Cancer Therapy and Research Center, University of Texas Health Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil
Status: Enrolling
Updated:  8/28/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil
Status: Enrolling
Updated: 8/28/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
A PHASE I TRIAL OF ALLOREACTIVE NK CELLS INFUSION FOLLOWING TRANSPLANTATION OF HAPLOTYPE MISMATCHED, KIR MISMATCHED HIGHLY PURIFIED CD34 CELLS IN PATIENTS WITH ADVANCED OR REFRACTORY MYELOID MALIGNANCIES
Status: Enrolling
Updated:  8/28/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
A PHASE I TRIAL OF ALLOREACTIVE NK CELLS INFUSION FOLLOWING TRANSPLANTATION OF HAPLOTYPE MISMATCHED, KIR MISMATCHED HIGHLY PURIFIED CD34 CELLS IN PATIENTS WITH ADVANCED OR REFRACTORY MYELOID MALIGNANCIES
Status: Enrolling
Updated: 8/28/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment
Status: Enrolling
Updated:  8/28/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment
Status: Enrolling
Updated: 8/28/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment
Status: Enrolling
Updated:  8/28/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment
Status: Enrolling
Updated: 8/28/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment
Status: Enrolling
Updated:  8/28/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment
Status: Enrolling
Updated: 8/28/2015
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma
Status: Enrolling
Updated:  8/31/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma
Status: Enrolling
Updated: 8/31/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  9/2/2015
Blood and Marrow Transplant Program at Northside Hospital
mi
from
Atlanta, GA
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 9/2/2015
Blood and Marrow Transplant Program at Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  9/2/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 9/2/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  9/2/2015
Hahnemann University Hospital
mi
from
Philadelphia, PA
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 9/2/2015
Hahnemann University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  9/2/2015
Icahn School.of Medicine at Mount Sinai
mi
from
New York, NY
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 9/2/2015
Icahn School.of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated:  9/3/2015
Orthopaedic Hemophilia Treatment Center
mi
from
Los Angeles, CA
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated: 9/3/2015
Orthopaedic Hemophilia Treatment Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated:  9/3/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated: 9/3/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated:  9/3/2015
University of Colorado, Hemophilia and Thrombosis Center
mi
from
Aurora, CO
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated: 9/3/2015
University of Colorado, Hemophilia and Thrombosis Center
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated:  9/3/2015
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated: 9/3/2015
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated:  9/3/2015
Rush University Medical Center
mi
from
Chicago, IL
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated: 9/3/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated:  9/3/2015
Republican Research Center for Radiation Medicine and Human Ecology
mi
from
Gomel,
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Status: Enrolling
Updated: 9/3/2015
Republican Research Center for Radiation Medicine and Human Ecology
mi
from
Gomel,
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Jonesboro, AR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Corona, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Corona, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Miami, FL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Wichita, KA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Mt Sterling, KY
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Mt Sterling, KY
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Bethesda, MD
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Detroit, MI
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Bismarck, ND
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Bismarck, ND
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Eugene, OR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Germantown, TN
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Germantown, TN
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Newport News, VA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Newport News, VA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Hot Springs, AR
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Fountain Valley, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Riverside, CA
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Evergreen Park, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Park Ridge, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Skokie, IL
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated:  9/7/2015
Sandoz Investigational Site
mi
from
Tucuman,
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
Status: Enrolling
Updated: 9/7/2015
Sandoz Investigational Site
mi
from
Tucuman,
Click here to add this to my saved trials
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
Status: Enrolling
Updated:  9/8/2015
Ohio State University
mi
from
Columbus, OH
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
Status: Enrolling
Updated: 9/8/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Pilot Study of Allogeneic Stem Cell Transplantation From Unrelated Donors for Patients With Severe Homozygous Beta 0/+ Thalassemia or Severe Variants of Beta 0/+ Thalassemia
Status: Enrolling
Updated:  9/9/2015
Texas Children's Hospital
mi
from
Houston, TX
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Pilot Study of Allogeneic Stem Cell Transplantation From Unrelated Donors for Patients With Severe Homozygous Beta 0/+ Thalassemia or Severe Variants of Beta 0/+ Thalassemia
Status: Enrolling
Updated: 9/9/2015
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/9/2015
Clinical Research Consultants, Inc.
mi
from
Hoover, AL
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/9/2015
Clinical Research Consultants, Inc.
mi
from
Hoover, AL
Click here to add this to my saved trials
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma
Status: Enrolling
Updated:  9/9/2015
Arizona Clinical Research Center
mi
from
Tucson, AZ
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma
Status: Enrolling
Updated: 9/9/2015
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials